We are live on ! Find out more
TAK icon

Takeda Pharmaceutical
TAK

93 hedge funds and large institutions have $910M invested in Takeda Pharmaceutical in 2018 Q4 according to their latest regulatory filings, with 93 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more call options, than puts

Call options by funds: $7.49M | Put options by funds: $4.34M

6.8% more ownership

Funds ownership: 0% → 6.8% (+6.8%)

Holders
93
Holders Change
+93
Holders Change %
–
% of All Funds
2.07%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
93
Increased
–
Reduced
–
Closed
–
Calls
$7.49M
Puts
$4.34M
Net Calls
+$3.14M
Net Calls Change
+$3.14M

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$171M
2
Bank of America
Bank of America
North Carolina
+$116M
3
Citigroup
Citigroup
New York
+$111M
4
Goldman Sachs
Goldman Sachs
New York
+$86.2M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$63.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$171M +$171M +10,148,596 New
Bank of America
2
Bank of America
North Carolina
$116M +$116M +6,898,473 New
Citigroup
3
Citigroup
New York
$113M +$111M +6,548,306 New
Goldman Sachs
4
Goldman Sachs
New York
$85.8M +$86.2M +5,103,619 New
Arrowstreet Capital
5
Arrowstreet Capital
Massachusetts
$63.4M +$63.7M +3,772,245 New
Northern Trust
6
Northern Trust
Illinois
$57.4M +$57.7M +3,414,999 New
MIP
7
Mondrian Investment Partners
United Kingdom
$48.9M +$48.5M +2,873,870 New
CCM
8
Causeway Capital Management
California
$37.1M +$37.2M +2,204,384 New
PPA
9
Parametric Portfolio Associates
Washington
$25.9M +$26M +1,541,957 New
CS
10
Credit Suisse
Switzerland
$23M +$23.1M +1,367,880 New
BIP
11
Brandes Investment Partners
California
$17.1M +$17.1M +1,013,882 New
EAM
12
Exane Asset Management
France
$15.7M +$15.8M +933,466 New
CI
13
Cowen Inc
New York
$14.4M +$14.5M +858,204 New
Jane Street
14
Jane Street
New York
$13.5M +$13.5M +801,303 New
Janus Henderson Group
15
Janus Henderson Group
United Kingdom
$11.5M +$11.5M +682,332 New
Citadel Advisors
16
Citadel Advisors
Florida
$9.71M +$9.74M +577,084 New
PC
17
Polar Capital
United Kingdom
$8.41M +$8.44M +500,000 New
AIMCA
18
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$7.2M +$7.23M +428,050 New
UBS AM
19
UBS AM
Illinois
$6.95M +$6.97M +412,966 New
MC
20
Maverick Capital
Texas
$6.48M +$6.5M +385,000 New
OAM
21
Oppenheimer Asset Management
New York
$5.22M +$5.24M +310,161 New
PNC Financial Services Group
22
PNC Financial Services Group
Pennsylvania
$4.89M +$4.91M +290,705 New
SEI Investments
23
SEI Investments
Pennsylvania
$4.88M +$4.87M +288,231 New
AG
24
Aperio Group
California
$4.02M +$4.04M +239,187 New
TAL
25
TIG Advisors LLC
New York
$3.59M +$3.6M +213,337 New
1
2 3 4

TAK Hedge Fund Activity: Q4 2018 in Review

93 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2018, worth a combined $910M.

Buyers outnumbered sellers: 93 funds opened new TAK positions and 0 closed out — a net gain of 93 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $171M.

  • 93 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2018, up from 0 in Q3 2018.
  • Funds reported $910M of Takeda Pharmaceutical stock for Q4 2018.
  • 93 funds opened new Takeda Pharmaceutical positions in Q4 2018 and 0 closed out, a net change of +93 holders.
  • The largest Takeda Pharmaceutical buyer in Q4 2018 was UBS Group, an estimated $171M added.

Based on aggregated 13F filings for Q4 2018.